Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.
Employees: 11-50
Total raised: $75M
Investors 4
| Date | Name | Website |
| 20.05.2025 | Avoro Capi... | avorocapit... |
| 22.06.2023 | Avego | avego.com |
| 25.07.2023 | TCG Crosso... | tcgcrossov... |
| 25.03.2024 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.10.2023 | - | $75M | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.10.2025 | Швейцарская Novartis покупает американскую биотехнологическую компанию Avidity за $12 млрд | Компания Novartis AG согласилась приобрести Avidity Biosciences Inc. за $12 млрд, что стало крупнейшей сделкой швейцарского производителя лекарств за последние более чем десять лет. Приобретение добавляет несколько потенциальных препаратов-... |
| 13.11.2024 | Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 | Prevent Blindness offers free educational materials for patients and healthcare professionals for its 5th Annual Thyroid Eye Disease Awareness Week. Prevent Blindness provides free educational materials on Thyroid Eye Disease, including a n... |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options. Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors WOODBUR... |
| 19.10.2023 | Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million | - |